title: [Radiation therapy with synchrotron radiation and cisplatin-based chemotherapy as a treatment of gliomas].
abstract: The application of synchrotron radiation in medicine dates back to more than one decade. In particular, a team of researchers led by Dr. F. Esteve has been working for several years in the Grenoble Synchrotron (ESRF) on radiotherapy treatments to heal brain tumors. The team has recently obtained a very promising new result. Gliomas the commonest brain tumor in the adult and the mean survival in advanced disease patients is lower than one year. Conventional radiation therapy is used palliatively since it is one of the most radiotherapy-resistant tumors. Moreover, chemotherapy and surgery have no utility in most cases. Experiments at the Grenoble Synchrotron have been carried out in mice with gliomas and they consist of injecting cysplatine into the tumors so that an intense monochromatic radiation is applied afterwards. Half-life of sick untreated mice is 28 days. With the use of cysplatine alone, it expands to 48 days. However, the association of two treatments supposes a half-life of 206 days (six times greater than in untreated mice). After one year of treatment, 34% of animals remain alive, which constitutes a result never seen before in this type of radio-resistant tumors.
authors.affiliation: ALBA Edificio Ciencias, C-3 central UAB, Bellaterra, Barcelona, Spain.
authors.forename: Salvador
authors.initials: S
authors.lastname: Ferrer
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D002945:Cisplatin / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005910:Glioma / Q000188:drug therapy* / Q000532:radiotherapy*; D051379:Mice; D017356:Synchrotrons
chemical_list: D000970:Antineoplastic Agents; D002945:Cisplatin